IP Library Granted Patent US 8,846,094
Granted Patent B2
US 8,846,094 · App. 11/828,561 · Granted Sep 30, 2014

Peripherally administered viscous formulations

Inventors: Robert T. Lyons (Laguna Hills, CA); Michael R. Robinson (Irvine, CA); John T. Trogden (Anaheim, CA); Scott M. Whitcup (Laguna Hills, CA)
Assignee: Allergan, Inc.
A61K31/56A61K47/02A61K47/36A61K47/40A61K31/715A61K47/34A61K31/573A61K9/0048A61K9/0019
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,846,094
App. No.
11/828,561
Granted
Sep 30, 2014
Kind
B2
Abstract

Viscous formulations and methods of using such compositions, useful for intramuscular and intra-articular injection are provided to treat peripheral conditions. Such compositions can include triamcinolone particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 80,000 cps to about 300,000 cps. In a most preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 280,000 cps at a shear rate of 0.1/second at 25° C. The compositions advantageously suspend the triamcinolone particles for prolonged periods of time.

Claims (5)

1. A method for treating arthritis, the method comprising the step of injecting into a joint of a patient with arthritis a viscous formulation comprising a plurality of corticosteroid particles, the plurality of corticosteroid particles having a median particle size of less than about 10 microns, mixed into a viscous polymeric matrix, wherein the viscous formulation has a viscosity of between about 130,000 cps and about 300,000 cps at a shear rate of about 0.1/second at about 25° C., and wherein the polymeric matrix comprises a) a cyclodextrin component and b) polymeric hyaluronate or a polymeric hyaluronic acid, and wherein the corticosteroid is triamcinolone.

2. The method of claim 1 , wherein the triamcinolone is triamcinolone actonide.

3. The method of claim 1 , wherein the triamcinolone is triamcinolone hexacetonide.

4. The method of claim 1 , wherein the cyclodextrin component is present at a concentration of about 0.5% (w/v) to about 5.0% (w/v).

5. The method of claim 4 , wherein the cyclodextrin component is selected from the group consisting of β-cyclodextrin and sulfo-butylether β-cyclodextrin.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2007
From: LYONS, ROBERT T.; ROBINSON, MICHAEL R.; TROGDEN, JOHN T.; WHITCUP, SCOTT M.
To: ALLERGAN, INC.
Reel/Frame 019612/0132 →
Continuity (6)
Continuation 11741366 · Apr 27, 2007
Continuation In Part 11354415 · Feb 14, 2006
Continuation In Part 10966764 · Oct 14, 2004
Provisional Application 60519237 · Nov 12, 2003
Provisional Application 60530062 · Dec 16, 2003
Related Publication 20080044476A1 · Feb 21, 2008